首頁
Boston Biomedical

11月 2025Boston Biomedical的市場佔有率分析

sumitomo pharma oncology is a global developer of novel cancer therapeutics. learn about our diverse and purposeful pipeline of targeted therapies.

健康 > 生物技術和製藥

域名bostonbiomedical.com

成立年份2006

僱員51 - 200

年度營收$15M - $25M

Boston Biomedical

Boston Biomedical（包含公司地區）

bostonbiomedical.com

查看更多網站流量與參與度資訊

Boston Biomedical截至 11月 2025 的總收入為 15M - 25M

Boston Biomedical 熱門網域產生的總收入

Boston Biomedical 熱門網域 3 年內的總收入

Boston Biomedical 熱門網域的總收入

bostonbiomedical.com15M - 25M

透過銷售情報查看更多內容

Boston Biomedical的熱門網域總造訪量

了解Boston Biomedical市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

無可顯示數據

Boston Biomedical的熱門網域平均造訪時長

分析Boston Biomedical參與度指標。

過去 3 個月平均造訪時長

無可顯示數據

Boston Biomedical的熱門網域平均頁面瀏覽量

了解Boston Biomedical如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

無可顯示數據

Boston Biomedical按網域劃分的熱門競爭對手

11月 2025的熱門類似網站，依相似度排名

chronixbiomedical.com公司名Chronix Biomedical僱員51 - 200總部美國, 加利福尼亞, San Jose年度營收$15M - $25M訪問總量--健康 > 生物技術和製藥

使用的熱門技術Boston Biomedical

这些是Boston Biomedical顶级域名使用的行业网站技术

付費廣告 (4)

DoubleClick

小工具 (4)

reCAPTCHA

內容管理系統 (2)

WordPress

音訊視訊媒體 (1)

YouTube

更多技術

7

檢視所有

新聞與訊號來自Boston Biomedical

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Sumitomo Pharma Co., Ltd acquired Bostonbiomedical for $2.63B on Jan 1st '12.If completed, the deal would rank as this year's fourth-largest disclosed global biopharma M&A transaction and Sumitomo Dainippon's most expensive acquisition to date, topping predecessor Dainippon Sumitomo Pharma's $2.63 billion acquisition of cancer-focused Boston Biomedical Inc. in 2012.

新聞Huebner leaves Bostonbiomedical as head of development.Huebner joined Mersana from Boston Biomedical, where he served as head of development.

新聞Bostonbiomedical hired Edgar Braendle as executive vice president, head of research and development, and chief medical officer on Oct 16th '17.Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics, today announced the appointment of Edgar Braendle, M.D., Ph.D., to Executive Vice President, Head of Research and Development and Chief Medical Officer.